Your patient's cells,
already inside them.
RenagenBio establishes turnkey USC laboratories within partner hospitals, enabling autologous stem cell therapies derived exclusively from patients' urine. No surgery, no donors, no rejection risk.
A decade of peer-reviewed research
Urine-Derived Stem Cells (USCs) were first identified in 2008 at Wake Forest Institute for Regenerative Medicine. Since then, over 200 peer-reviewed publications have validated their isolation, expansion, and therapeutic potential across multiple tissue types.
Non-invasive collection
Unlike bone marrow or adipose-derived MSCs, USCs are obtained from a standard urine sample. No biopsy, no anaesthesia, no hospital admission required for collection.
Rapid expansion
Under controlled culture conditions, a single urine sample yields 3.7 x 108 therapeutic cells within 27 days. Cells maintain genomic stability through 15 passages.
Autologous, zero rejection
Because cells originate from the patient, there is no immunological rejection and no need for immunosuppression therapy. This is a fundamental clinical advantage over allogeneic approaches.
Multi-lineage potential
USCs differentiate into osteogenic, chondrogenic, smooth muscle, endothelial, and urothelial lineages. Therapeutic preclinical evidence spans renal injury, osteoarthritis, skin wounds, diabetes, and cardiac fibrosis.
Validated cryopreservation
A robust cryopreservation protocol for USCs was validated and published in the European Journal of Clinical Investigation (2026), enabling long-term banking and logistics across geographies.
iPSC reprogramming
USCs can be reprogrammed into induced pluripotent stem cells (u-iPSCs), expanding their application scope to disease modelling, drug testing, and future pluripotent cell therapies.
Preclinical evidence across conditions
All indications below have demonstrated positive outcomes in peer-reviewed preclinical studies. Our initial clinical research protocol targets osteoarthritis, the highest-prevalence indication among international patients seeking regenerative care.
| Indication | Evidence stage | Mechanism | Strategic priority |
|---|---|---|---|
| Osteoarthritis (knee/hip) | Preclinical ✓ | Chondrogenic differentiation, anti-inflammatory paracrine | Lead indication |
| Acute kidney injury | Preclinical ✓ | Homing to injured nephrons, reduced KIM-1 expression | Phase 2 target |
| Chronic wound / skin repair | Preclinical ✓ | Macrophage M2 polarisation, scar-free healing | Phase 2 target |
| Type 2 Diabetes | Preclinical ✓ | Differentiation into insulin-producing beta cells | Phase 3 target |
| Stress urinary incontinence | Preclinical ✓ | Sphincter muscle regeneration | Phase 3 target |
| Cardiac fibrosis | Preclinical ✓ | Reduced myocardial fibrosis, paracrine signalling | Long-term |
A laboratory inside your hospital.
Zero capital investment from you.
RenagenBio installs and operates a fully equipped USC laboratory within your facility under a joint research protocol. We provide the technology, equipment, and scientific team. You provide the space, the existing patient pipeline, and the institutional credibility.
- Laboratory space (25 to 40 m²)
- Existing international patient pipeline
- Ethics committee review and institutional approval
- Treating physician (applies the therapy)
- COFEPRIS institutional licence (existing)
- Co-authorship on published research
- Full laboratory equipment and installation
- Proprietary USC isolation and expansion protocol
- Trained cell biology team (on-site)
- Research protocol design and ethics submission support
- Remote urine collection kit logistics for US-based patients
- Revenue share per treated patient
The partnership operates under a formal research protocol approved by the hospital's ethics committee. All patients provide written informed consent. The treating physician at your institution assumes clinical responsibility for administration.
From collection to therapy in four steps
Patients in the United States initiate the process remotely. They travel to your facility only once, when their cells are ready for administration.
Remote urine collection
The patient receives a collection kit by mail at their US address. They collect a urine sample and ship it to the laboratory via FedEx or DHL under standard biological sample protocols. No travel required at this stage.
Day 1USC isolation and expansion
The laboratory team isolates progenitor cells from the sample using centrifugation and selective culture. Cells are expanded under GMP-grade conditions in a controlled hypoxic environment with collagen matrix.
Days 2 to 27Quality verification and patient notification
Cell counts, viability, sterility and surface marker panels are validated. Once therapeutic volume is confirmed, the patient is notified and schedules their single visit to the partner hospital.
Days 27 to 30Administration at partner hospital
The treating physician at your hospital administers the autologous USC preparation, intra-articular, intravenous or topical depending on the indication. Cells are the patient's own, so rejection risk is eliminated.
Single visitThe first mover window is open
No hospital in the medical tourism corridor currently offers USC-based autologous therapy. The preclinical science is robust. The logistics are solved. Patient demand for non-surgical regenerative options is growing year over year.
The clinical research infrastructure we establish together will position your institution as a global reference centre for this modality, before pharmaceutical players arrive.
Schedule an exploratory callLet's explore a partnership
We are currently in active discussions with hospitals in Mexico and Latin America with established international patient programmes. If your institution meets the profile, we would welcome an initial conversation.
Ideal partner profile:
- Private hospital or specialty clinic in Mexico, Panama or Colombia
- Active programme serving US or Canadian patients
- Existing or adjacent regenerative medicine or orthopaedics department
- Institutional ethics committee in place